MIRDC established the “Biotechnology and Medical Innovation and Industrialization Alliance” at Garden Villa, Kaohsiung on December 11th, 2018 (Tuesday), dedicated to the promotion of Taiwan biotechnology and medical innovation businesses. Dr. Chiu-hsiung Lin, the Chairman of Lin & Associates, LLC and Ms. Mei-Hsueh Lin, the General Manager of TransPacific Venture Partners were invited to give the speeches of “How to Accelerate R&D and Innovation of Medical Devices in Taiwan” as well as “Recommendations for Taiwan Innovation Business on the Perspective of Global Venture Capital”. The great conference attracted hundreds of guests.
Members of the Alliance are composed of the elites from the fields of industry, official, academia, research institutes, foreign associations, regulations, finance, venture capital, and mentors, including Professor Chun-Pin Lin, from School of Dentistry NTU, Professor Heng-Er Hung, from NTNU, Professor Chih-Han Chang, from Research and Services Headquarter, NCKU, Hsien-Chi Pei, the CEO of Center for Academia and Industry Collaboration, NYMU, Pei-Yuan Li, the Director of Show Chwan Memorial Hospital, Li-Che Huang, the Chief of Office for Operation of Industry and University Cooperation, KMU, Hsiu-Chin Chung, the Senior Manager of Industrial Liaison Office, NSYU, Jen-Yi Lin, Chairman of MIRDC as well as Ying-Chieh Lin, the Acting Director of Industrialization Promotion Center, Chih-Lung Lin, the President of Taiwan Industrial Technology Association (TITA), Po-Shun Peng, the Counselor of Taiwanese American Industrial Technology Association (TAITA), Hung-Te Chang, the former President of North America Taiwanese Engineering & Science Association (NETEA), Chiu-Hsiung Lin, Chairman of Lin & Associates, LLC, A-Shen Liao, Accountant of PwC Taiwan, Hung-Jen Chen, the Manager of Agricultural Bank, Yen-Jung Liu, the CEO of StarFab Accelerator, Mei-Hsueh Lin, General Manager of TransPacific Venture Partners, and Cheng Chang, the Entrepreneurship Mentor of Small and Medium Enterprise Administration, MOEA. All of them stated that they could contribute to start-up businesses in Taiwan.
Chih-Lung Lin, the Vice President of MIRDC (as well as the President of TITA) indicated that the Alliance aims to take the advantages of local clinical innovative R&D and evidence-based medicine, together with experiences of mentors, to give the most practical assistance to the innovation team. Meanwhile, they would support the upgrade and transition of existing biotechnological companies, integrating critical resources of academia, research institute, venture capital, finance, and regulations to promote the thriving development of biotechnological industries in Taiwan.
He also pointed out that more and more investors of institutes and pharmaceutical manufacturers had emerged in the market due to the fast-advancing biotechnology. The development of innovation business in the future should bring Taiwan or Asian features, clinical resources, and data into the developed items depending on the clinical medical environment and advantages of ICT industry in Taiwan in order to attract manufacturers and investors around the world. It is hoped that, with experts’ assistance, the start-up businesses in Taiwan can develop and grow, eventually stand on the world stage!